Category Archives: Global News Feed

-- 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection ---- BA.5 neutralizing antibody levels were approximately two to four-fold higher than BA.1 neutralizing antibody levels, demonstrating a potentially differentiated breadth of neutralization against the globally dominant BA.5 subvariant by SCB-2019 (CpG 1018/Alum) vaccination --

See the original post here:
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.

Originally posted here:
Novartis presents new data in breast and prostate cancer at ESMO

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2022.

Read more from the original source:
Mesoblast Corporate Update and Financial Results Webcast

FDA grants priority review to efanesoctocog alfa for people with hemophilia A

Go here to read the rest:
Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

LONDON and NEW YORK and NORTH AUGUSTA, S.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022 IND filing for OK-101 to treat dry eye disease (DED), with AmbioPharm playing a key role in peptide manufacturing and development.

View original post here:
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner,...

LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in mainland China.

View post:
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results today. The presentation by the company's management team can be followed as a live webcast at 09:00 CET and will be made available on the website. It will be possible to post questions during the presentation through the webcast.

Read the original post:
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update

The pre-funded warrants were issued as part of the $10 million private placement from June 2022

See the original post:
Scisparc Announces the Full Exercise of Pre-Funded Warrants

Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an Oral Presentation on Saturday, September 10 (16:55 CEST; 10:55 a.m. ET) Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an Oral Presentation on Saturday, September 10 (16:55 CEST; 10:55 a.m. ET)

Continued here:
SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress...

SHANGHAI, China, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced today that the US Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) to our fixed-dose combination capsule of Senaparib (PARP inhibitor) and temozolomide (TMZ) for the treatment of adult patients with small cell lung cancer (SCLC).

Go here to see the original:
FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC